Archive · 31 Jul 2026
Sun Pharma Q1 FY27 Net Profit Rises 27% to ₹2,894.8 Crore
Sun Pharma is a big drug company in India.
In the first part of its 2027 financial year, it made more money than last year, earning about ₹2,895 crore after taxes.
Its total sales went up to about ₹15,184 crore.
The company spent about ₹11,721 crore on everything, including paying its workers.
It had some extra costs from buying another company and new labor rules, but it also got a tax credit that helped.
The profit per share was ₹12.1, higher than the ₹9.5 it earned last year, and its earnings before interest, taxes, depreciation, and amortization (EBITDA) margin was 28.9%.
Net profit after tax for Q1 FY27 reached ₹2,894.8 crore, up 27% from ₹2,278.6 crore in Q1 FY26.
Consolidated revenue rose to ₹15,183.55 crore, a 10.1% increase over ₹13,786.07 crore in the same period last year.
Total expenses climbed to ₹11,720.60 crore, with employee benefits expense at ₹3,227.23 crore.
Exceptional items of ₹204.09 crore included a ₹167 crore acquisition cost for Organon & Co. and a ₹37.09 crore cost related to New Labour Codes, partially offset by a ₹9.43 crore tax credit.
Basic and diluted earnings per share were ₹12.1, up from ₹9.5, and EBITDA margin stood at 28.9%.
- Who
- Sun Pharmaceutical Industries Ltd
- What
- First‑quarter financial results for fiscal year 2027
- When
- Quarter ended June 30, 2026
- Where
- Mumbai, India
- Why
- Not explicitly stated; results reflect company performance
- Net profit after tax
- ₹2,894.8 crore
- Consolidated revenue
- ₹15,183.55 crore
- Total expenses
- ₹11,720.60 crore
- Exceptional items
- ₹204.09 crore
- Earnings per share
- ₹12.1
- EBITDA margin
- 28.9%